- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03982381
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST)
A Multicenter, Register-based, Randomized, Controlled Trial Comparing Dapagliflozin With Metformin Treatment in Early Stage Type 2 Diabetes Patients by Assessing Mortality and Macro- and Microvascular Complications
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
2067 type 2 diabetes (T2D) patients on monotherapy or drug naive. Randomization 1:1, metformin, dosing according to treatment guidelines or SGLT2 inhibitor, dapagliflozin 10 mg od.
844 events estimated for study completion (90% power to detect hazard ratio (HR) <0.8 for dapagliflozin vs metformin ) Endpoint collection during study duration (about 4 years) from national health care registers: Patient, Prescribed drugs, Cause of death and Population registers; National diabetes register (NDR) Primary analysis according to insulin tolerance test (ITT)
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jan Eriksson, MD
- Phone Number: +46 738 681133
- Email: jan.eriksson@medsci.uu.se
Study Contact Backup
- Name: Sofia Löfving, RN
- Phone Number: +46 18 6113571
- Email: sofia.lofving@medsci.uu.se
Study Locations
-
-
-
Uppsala, Sweden, 75185
- Uppsala University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women ≥18 years old
- T2D (according to World Health Organization (WHO) criteria) of less than 4 years duration
- BMI 18.5-45 kg/m2
- Drug naïve or oral monotherapy with glucose-lowering drug.
- Accepting NDR participation and other register data collection.
Exclusion Criteria:
- Known or suspected other form of diabetes than type 2
- Ongoing or more than >4 weeks in total of any previous treatment with: insulin, GLP-1 receptor agonists, SGLT2 inhibitors or combination of any diabetes medications
- Medical need to start or intensify any specific GLD treatment, e.g. insulin due to marked hyperglycemia
- HbA1c >70 mmol/mol for patients on monotherapy, >80 in drug naïve
- Contraindication to either metformin or dapagliflozin, or any unacceptable risk with either treatment as assessed by the investigator
- History or signs of established cardiovascular disease: diagnosis of myocardial infarction, angina pectoris, heart failure, stroke, lower extremity arterial disease, any limb amputation (except due to trauma or malignancy)
- Any serious illness or other condition with short life expectancy (<4 yr)
- Renal impairment (eGFR <60 ml/min/1,73m2)
- Any condition, as judged by the investigator, that suggests that the patient will be non-compliant or otherwise unsuitable to study medication or study participation
- Pregnancy or breastfeeding, women of childbearing potential (WOCBP; including perimenopausal women who have had a menstrual period within 1 year) without adequate anticonception during any part of the study period
- Involvement in the planning and/or conduct of the study
- Ongoing participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin
Metformin 1000-3000 mg per day according to clinical guidelines.
Split into 2-3 doses per day.
|
Active comparator
|
Experimental: Dapagliflozin
Dapagliflozin 10 mg once daily
|
Experimental treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
A confirmed composite endpoint includes death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer (ICD10 diagnosis codes)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ordinal analysis of components of primary endpoint (see above)
Time Frame: Events of any of above having occurred during 48 months following randomization.
|
Death, major adverse cardiovascular event or microvascular event at 2 years follow-up (ICD10 diagnosis codes), scored according to severity as specified in statistical analysis plan.
|
Events of any of above having occurred during 48 months following randomization.
|
Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer (ICD10 diagnosis codes) or initiation of insulin treatment.
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
A confirmed composite endpoint includes death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer (ICD10 diagnosis codes) or initiation of insulin treatment (filled prescription according to Swedish Prescribed Drug Register)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Time to first occurence of a confirmed composite endpoint of non-fatal myocardial infarction, stroke, heart failure, unstable angina or cardiovascular death.
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
A confirmed composite endpoint includes non-fatal myocardial infarction, stroke, heart failure, unstable angina or cardiovascular death (ICD10 diagnosis codes).
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Time to first occurence of a confirmed composite endpoint of heart failure or cardiovascular death.
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
A confirmed composite endpoint includes heart failure or cardiovascular death (ICD10 diagnosis codes)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Death
Time Frame: Time to event during study period (for each patient 24-48 months, mean 36 months)
|
Time to death (Population Register data)
|
Time to event during study period (for each patient 24-48 months, mean 36 months)
|
Microvascular events, first of; occurrence or progression of retinopathy, nephropathy, diabetic foot lesions
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Time to first event of: occurrence or progression of retinopathy, nephropathy, diabetic foot ulcers (ICD10 diagnosis codes)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Need for insulin treatment
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Time to initiation of insulin treatment (filled prescription according to Swedish Prescribed Drug Register)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Treatment failure, defined as add-on or switch to another glucose-lowering drug
Time Frame: Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Time to event of: add-on or switch to another glucose-lowering drug (filled prescription according to Swedish Prescribed Drug Register)
|
Time to first event during study period (for each patient 24-48 months, mean 36 months )
|
Change in glycemic control
Time Frame: Change during study period, at 12, 24, 36 and 48 months
|
HbA1c level (mmol/mol)
|
Change during study period, at 12, 24, 36 and 48 months
|
Change in LDL-cholesterol
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in LDL cholesterol from baseline (mmol/L)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in HDL-cholesterol
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in HDL cholesterol from baseline (mmol/L)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in total cholesterol
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in total cholesterol from baseline (mmol/L)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in triglycerides
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in triglycerides from baseline (mmol/L)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in albuminuria
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in urinary albumin/creatinine ratio (mg/mol)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in blood pressure
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in systolic and diastolic blood pressure (mm Hg)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in body weight
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in body weight (kg)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in BMI
Time Frame: Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Change in BMI (kg/m2)
|
Change during study period; assessment at baseline, 12, 24, 36 and 48 months
|
Health care costs
Time Frame: Accumulated health care costs during study period (for each patient 24-48 months, mean 36 months )
|
Diagnosis-based (IDG) costs for all health care during study period plus medication cost
|
Accumulated health care costs during study period (for each patient 24-48 months, mean 36 months )
|
Health-related quality of life
Time Frame: Assessment at baseline, 12, 24 months
|
The Short Form 36-Item Survey version 1.0 (SF-36) is used for patient-reported health and consists of 36 questions.
The weighted sums of scores in each of eight defined domains (relating to experience of different aspects of general health, symptoms and functions) are compiled into different scales according to a standardized algorithm.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability, i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
We use the public domain version, called the the RAND-36 Item Health Survey.
|
Assessment at baseline, 12, 24 months
|
Health-related quality of life with respect to diabetes treatment satisfaction.
Time Frame: Assessment at baseline, 12, 24 months
|
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is used.
It has been developed to assess patient satisfaction with diabetes treatment.
The questionnaire is composed of two different factors.
The first factor assesses treatment satisfaction and consists of six questions and the second factor consists of two questions, which assess the burden from hyper- and hypoglycemia.
Treatment satisfaction is assessed as the sum of the scores of the six questions on the first factor (total score 36), with a higher score indicating higher treatment satisfaction.
|
Assessment at baseline, 12, 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jan Eriksson, MD, Uppsala University
Publications and helpful links
General Publications
- Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.
- Sundstrom J, Kristofi R, Ostlund O, Bennet L, Eliasson B, Jansson S, Leksell J, Almby K, Lundqvist M, Eriksson JW; SMARTEST study group (see list in Appendix). A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications. 2021 Oct;35(10):107996. doi: 10.1016/j.jdiacomp.2021.107996. Epub 2021 Jul 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMART-2019
- 2019-001046-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland